PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an upcoming Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum.
Kalaris to Participate at Stifel Ophthalmology Forum
Seeking Alpha / 2 hours ago 2 Views
Comments